gms | German Medical Science

29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Hochdruckliga e. V. DHL ® - Deutsche Hypertonie Gesellschaft Deutsches Kompetenzzentrum Bluthochdruck

23. bis 25.11.2005, Berlin

Preterax in German patients with a new diagnosis of hypertension: results of the PRIMUS study

Preterax zur Behandlung deutscher Patienten mit Erstdiagnose einer Hypertonie: Ergebnisse der PRIMUS Studie

Meeting Abstract

  • P. Trenkwalder - Klinikum Starnberg (Starnberg, D)
  • H. Holzgreve - Internist - Kardiologischer Praxis (München, D)
  • T. Risler - Universität Tübingen (Tübingen, D)

Hypertonie 2005. 29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Berlin, 23.-25.11.2005. Düsseldorf, Köln: German Medical Science; 2006. Doc05hochP65

The electronic version of this article is the complete one and can be found online at:

Published: August 8, 2006

© 2006 Trenkwalder et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Rationale: Recent guidelines (ESH/ESC, German Hypertension League) recommend low-dose combinations (LDC) for initial treatment of hypertension (HT). Preterax®, consisting of ACE-inhibitor perindopril 2 mg and diuretic indapamide 0.625 mg, is the only LDC approved for first-line antihypertensive therapy in several European countries including Germany.

Objective: To evaluate in general practice the efficacy and tolerability of Preterax® in German patients with a new diagnosis of HT.

Design: For this prospective, open-labelled, multicenter trial, 1892 GPs in Germany recruited 8023 patients with HT (SBP>140 and/or DBP>90), including 3015 with a new diagnosis of HT. Treatment consisted of Preterax®o.i.d. for 12 weeks, doubling of the dose was possible. SBP, DBP, normalization rate (SBP/DBP <140/90 mm Hg), responder rate (SBP/DBP <140/90 and/or SBP reduction >15 and/or DBP reduction >10 mm Hg), efficacy and tolerability according to GP`s judgement (from "excellent" to "insufficient") were evaluated. A descriptive statistical analysis was performed.

Results: Mean age in the 3015 patients with a new diagnosis of HT was 55.2 (+11.5) years. Baseline SBP was 166.1 (+13.8), DBP 97.2 (+8.6) mm Hg. 83.2% of patients had Stage 2 or 3 HT, and 84% had additional risk factors (according to current HT guidelines). In 8.3% of patients dose of Preterax® was doubled during treatment. Preterax® decreased SBP by 30.5 (+13.8) and DBP by 15.3 mm Hg (+9.2). Responder rate was 98%, and normalization rate for all patients 54,2% and 77,6% in patients with Stage 1 HT. Both efficacy and tolerability of Preterax® were evaluated as "excellent/good" in 90% of patients. No unexpected adverse effects were observed.

Conclusion: The LDC Preterax® showed excellent antihypertensive efficacy and tolerability in a large population of German patients with a new diagnosis of HT. These results in daily practice confirm that Preterax® is a suitable first-line treatment of HT, as recommended in recent guidelines.